Key Insights

Highlights

Treatment Research

5 treatments under study, led by Pricktestlösung B2 Gräserpollen 10000 Duml Odc

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
SYF5874787e291144e4ad0815427dd35e14Phase 3Recruiting

Long-term clinical trial of PQ Grass in paediatric subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by grass pollen

Showing all 1 trials

Research Network

Common Treatments

  • Pricktestlösung B2 Gräserpollen 10000 Duml Odc1
  • Bencard Pricktestlösung Negativkontrolle1
  • Histaminkontrollösung 1 Pricktestlösung Wirkstoff Histamindihydrochlorid1
  • Placebo With Mct Suspension For Injection Subcutaneous Use1
  • Pollinex Quattro Grass 10 Ml1

Active Sponsors

  • Allergy Therapeutics (UK) Limited1

Activity Timeline